Kerrisdale Capital on the China Medical Short Saga

Kerrisdale Capital on the China Medical Short Saga
PeteLinforth / Pixabay

Kerrisdale Capital on the China Medical Short Saga

The famous short selling hedge fund, Kerrisdale Capital, is out with its Q3 letter.

Kerrisdale Partners LP achieved a quarterly return, net to investors, of 9.1% for the quarter ended September 30, 2012. The S&P 500 index returned 6.4% during that time.
Since inception, the fund has achieved a return, net to investors, of 742.3%. The S&P 500 index has returned 67.6% during that time.
They detail an extremely interesting story about shorting of a potential fraud in the letter:

Today, the China Medical Technologies, Inc. (PINK:CMEDQ)  saga is over, and we can do an appropriate post-mortem. We established our initial short position in China Medical in the fourth quarter of 2012, when Glaucus Research published a report alleging that China Medical Technologies, Inc. (PINK:CMEDQ) management was committing fraud. We generated some returns from the position and at the end of the year assumed that China Medical would just become one of the many Chinese fraudcaps that populated our general short basket at the time.

Consistency is what makes the top 50 best-performing hedge funds so strong

Every month and quarter, multiple reports on average hedge fund returns are released from several sources. However, it can be difficult to sift through the many returns to uncover the most consistent hedge funds. The good news is that Eric Uhlfelder recently released his "2022 Survey of the Top 50 Hedge Funds," which ranks the Read More

Kerrisdale Capital Q3

Updated on

No posts to display